## Supporting information

## Intelligent tumor microenvironment responsive nanotheranostic agent for T1/T2 dual-modal magnetic resonance imaging-guided and self-augmented photothermal therapy

Junlie Yao,<sup>‡a,b</sup> Fang Zheng,<sup>‡a</sup> Fang Yang,<sup>‡\*a,c,d</sup> Chenyang Yao,<sup>a,b</sup> Jie Xing,<sup>a,b</sup> Zihou Li,<sup>a</sup> Sijia Sun,<sup>a</sup> Jia Chen,<sup>a</sup> Xiawei Xu,<sup>a</sup> Yi Cao,<sup>a,b</sup> Norbert Hampp,<sup>d</sup> and Aiguo Wu<sup>\*a,c</sup>

<sup>a</sup>Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices & Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo 315201, P. R. China.

<sup>b</sup>College of Materials Sciences and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100049, P. R. China.

<sup>c</sup>Advanced Energy Science and Technology Guangdong Laboratory, Huizhou 516000, P.R. China

<sup>d</sup>Fachbereich Chemie, Philipps Universität Marburg, Marburg, 35032, Germany

\*corresponding author: yangf@nimte.ac.cn (F. Y.); aiguo@nimte.ac.cn (A. W.)



Fig. S1 SAED pattern of Zn<sub>0.2</sub>Fe<sub>2.8</sub>O<sub>4</sub>@PDA@MnO<sub>2</sub> NPs.



Fig. S2 XPS survey spectrum of  $Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2 NPs$ .



**Fig. S3** Zeta potentials of CTAC modified  $Zn_{0.2}Fe_{2.8}O_4$  NPs,  $Zn_{0.2}Fe_{2.8}O_4$ @PDA NPs, and  $Zn_{0.2}Fe_{2.8}O_4$ @PDA@MnO<sub>2</sub> NPs under aqueous condition. Data are presented as the mean ± SD (n = 3).



Fig. S4 Heating and cooling curve of  $Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2 NPs$  (150 µg mL<sup>-1</sup>) irradiated by 808 nm laser irradiation (1.5 W cm<sup>-2</sup>).



Fig. S5 Linear time data obtained from the nature cooling period.



**Fig. S6** UV-vis absorption spectra of Zn<sub>0.2</sub>Fe<sub>2.8</sub>O<sub>4</sub>@PDA NPs with/without GSH (10 mM). Inset: Colour change of the Zn<sub>0.2</sub>Fe<sub>2.8</sub>O<sub>4</sub>@PDA NPs dispersion after adding 10 mM GSH.



Fig. S7 •OH measurement via ESR spectra ( $Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2 NPs: 150 \ \mu g \ mL^1$ ,  $H_2O_2$ : 1 mM).



Fig. S8 Cell viability of 4T1/MCF-7 cells co-incubated with  $Zn_{0.2}Fe_{2.8}O_4$ @PDA NPs (0-200 µg mL<sup>-1</sup>).



Fig. S9 Cell viability of 4T1 cells incubated with  $H_2O_2$  (0-200  $\mu$ M) and  $Zn_{0.2}Fe_{2.8}O_4$ @PDA@MnO<sub>2</sub> NPs (150  $\mu$ g mL<sup>-1</sup>).



Fig. S10 Degradation of MB (10  $\mu$ g mL<sup>-1</sup>) after incubating with GSH-treated Zn<sub>0.2</sub>Fe<sub>2.8</sub>O<sub>4</sub>@PDA@MnO<sub>2</sub> NPs (Mn: 500  $\mu$ M, H<sub>2</sub>O<sub>2</sub>: 10 mM, 60 min) in the NaHCO<sub>3</sub>/5% CO<sub>2</sub> buffer solution at various temperature.



Fig. S11 Mean fluorescence intensity of DCF in 4T1 cells after different treatments  $(Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2 NPs: 150 \ \mu g \ mL^{-1}; H_2O_2: 100 \ \mu M).$ 



Fig. S12 Representative digital photographs of the mice under different treatments on day 12.



**Fig. S13** Bio-distribution of the Fe element in major organs at 0, 24, and 48 h after intravenous injection of Zn<sub>0.2</sub>Fe<sub>2.8</sub>O<sub>4</sub>@PDA@MnO<sub>2</sub> NPs (100 μL, 4 mg mL<sup>-1</sup>).



Fig. S14 Bio-distribution of the Mn element in major organs at 0, 24, and 48 h after intravenous injection of  $Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2 NPs$  (100 µL, 4 mg mL<sup>-1</sup>).



Fig. S15 Immunohistochemical analysis of the expression of HSP70 on the tumor tissues exposed to 808 nm laser irradiation (1.5 W cm<sup>-2</sup>) after intratumoral injection of saline,  $Zn_{0.2}Fe_{2.8}O_4@PDA$  NPs or  $Zn_{0.2}Fe_{2.8}O_4@PDA@MnO_2$  NPs (100 µL, 4 mg mL<sup>-1</sup>).